Significant improvement of refractory cutaneous lesions of lupus erythematosus with the use of anifrolumab: a report of two cases

Anifrolumab, a monoclonal antibody targeting the interferon-1 receptor, is currently approved for the treatment of moderate- to-severe systemic lupus erythematosus, but emerging evidence highlights its potential efficacy in cases with predominant cutaneous involvement. We present two cases illustrat...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Gilberto P. da Rosa, Isabel Antunes, Bárbara V. Granja, Patrícia Gomes, Rúben Costa, Filomena Azevedo, Alberto Mota
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Sociedade Portuguesa de Dermatologia e Venereologia 2025-07-01
Serie:	Revista da Sociedade Portuguesa de Dermatologia e Venereologia
Soggetti:	Cutaneous lupus erythematosus. Discoid lupus erythematosus. Anifrolumab. Subacute cutaneous lupus erythematosus.
Accesso online:	https://www.portuguesejournalofdermatology.com/frame_eng.php?id=265
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!